evipedia.ai ← Back

Cissus quadrangularis for Health & Longevity

Evidence Review created on 08/02/2026 using AI4L / Opus 4.8

Also known as: Veldt Grape, Winged Treebine, Adamant Creeper, Devil’s Backbone, Hadjod, Asthisamharaka, Pirandai, Nalleru, CQ, Cissus quadrangula, Vitis quadrangularis, CQR-300

Motivation

Cissus quadrangularis is a thick, square-stemmed climbing plant in the grape family that grows across the drier parts of India, Africa, and Southeast Asia. For centuries it has been used in traditional medicine as a “bone-setter” — its Indian name Hadjod literally means “bone joiner” — to speed the healing of broken bones and ease joint and muscle pain. Today it is sold worldwide as an oral supplement, mainly for bone and joint support and weight management.

Interest from the health and longevity community grew after trials suggested the plant’s extracts might reduce body fat and improve metabolic markers such as blood sugar and cholesterol. Alongside this, laboratory work has pointed to antioxidant and anti-inflammatory activity, two themes that recur across many longevity-oriented interventions. The plant is inexpensive, widely available, and has a long record of everyday food and medicinal use.

This review examines what the evidence actually shows about Cissus quadrangularis across bone health, body composition, metabolic markers, and safety. It weighs the strength of the human trials against the large body of animal and test-tube work, and notes where commercial interests and small study sizes make the picture harder to read.

Benefits - Risks - Protocol - Conclusion

This section collects high-quality overviews and expert commentary that discuss Cissus quadrangularis by name and give a broad picture of its uses and evidence.

Grokipedia

  • Cissus quadrangularis

    The Grokipedia entry covers the plant’s taxonomy, distribution, traditional uses, phytochemistry, and the state of scientific research, providing a broad reference-level orientation to the topic.

Examine

  • Cissus quadrangularis

    Examine’s independent, evidence-graded supplement page summarizes the human research on bone healing, joint pain, and weight management, emphasizing how limited the controlled human data remain.

ConsumerLab

No dedicated ConsumerLab article exists for Cissus quadrangularis; the plant is referenced only as an ingredient inside broader bone-health supplement reviews rather than as its own reviewed product.

Systematic Reviews

The following systematic reviews and meta-analyses (studies that statistically pool results from multiple trials) represent the highest tier of human evidence on Cissus quadrangularis, selected for relevance, size, and recency.

Mechanism of Action

Cissus quadrangularis is a botanical extract rather than a single drug, so its effects arise from a mixture of active compounds — flavonoids, stilbenes (including resveratrol-type molecules), triterpenes, plant sterols, iridoids, vitamin C, carotenoids, and calcium-rich mineral content. Because it is a multi-constituent plant extract, classic single-molecule pharmacology (a defined half-life, receptor selectivity, and metabolism through specific liver enzymes) is not well characterized, and most mechanisms below come from animal and cell studies.

The proposed mechanisms fall into three groups:

  • Bone building. Extracts push bone-forming cells (osteoblasts) toward maturation and mineral deposition while dampening the formation of bone-dissolving cells (osteoclasts). In cell and animal work this is linked to blocking RANKL (a signaling protein that drives creation of bone-dissolving cells) and to a mild phytoestrogen effect — plant molecules that weakly mimic estrogen, a hormone important for maintaining bone.

  • Fat and metabolism. In fat-cell studies the standardized extract CQR-300 reduces the activity of PPAR-γ (a master switch for fat-cell formation) and related fat-storage genes, and one human-tissue study found it raised UCP1 (uncoupling protein 1, which lets fat cells burn energy as heat), a “browning” effect. Animal work also points to activation of AdipoR1 (a receptor for the fat hormone adiponectin) and to improved insulin sensitivity.

  • Antioxidant and anti-inflammatory activity. The high polyphenol and vitamin C content scavenges free radicals and lowers inflammatory signaling; animal studies additionally report effects on eNOS (an enzyme that makes nitric-oxide to relax blood vessels) and on the RAAS (renin–angiotensin–aldosterone system, a hormone network that controls blood pressure).

Competing interpretations exist. Supporters argue these overlapping actions explain the plant’s traditional bone and metabolic uses, while critics note that most mechanisms are demonstrated only at high doses in animals or isolated cells, that the “active” constituent is rarely pinned down, and that human confirmation is largely absent.

Historical Context & Evolution

Cissus quadrangularis has one of the oldest and most specific traditional reputations of any medicinal plant. In Ayurvedic and Siddha medicine it is called Asthisamharaka and Hadjod — both meaning roughly “that which joins bone” — and was applied, often as a paste or juice, to speed the mending of fractures, sprains, and dislocations, and to relieve joint pain, piles, and digestive complaints. Similar bone-setting uses are recorded across Africa and Southeast Asia, where the young stems are also eaten as a vegetable.

The plant came to be considered for modern health optimization along two paths. First, mid-twentieth-century Indian researchers began testing the traditional fracture claim in animals and reported faster bone healing, which drew scientific attention to its bone-active constituents. Second, in the 2000s a series of human trials from a commercial research group explored a standardized extract for weight loss and metabolic syndrome, repositioning the plant as a metabolic supplement for a Western market.

The historical fracture-healing findings were genuine positive results in animal models and small human studies, not merely folklore — early work described measurable improvements in bone mineral content and healing speed. Rather than being dismissed, that early evidence has been repeatedly re-examined; later reviews confirm a consistent bone-healing signal in animals but stress that rigorous, well-controlled human trials remain scarce. Scientific opinion has thus shifted from uncritical enthusiasm toward cautious interest: the plant is now viewed as biologically plausible and very safe, but not yet proven at the standard modern medicine expects, with new preclinical work on osteoporosis and metabolism continuing to emerge on both supportive and skeptical sides.

Expected Benefits

Content below is framed for risk-aware adults actively optimizing health and longevity, who may accept an inexpensive, well-tolerated botanical on modest evidence while tracking objective markers. Several key weight-loss trials were funded by or conducted with the commercial developer of the standardized CQR-300 extract (Gateway Health Alliance / researcher Julius Oben), a conflict of interest that should temper how strongly the metabolic findings are read.

Medium 🟩 🟩

Body Weight and Metabolic Syndrome Reduction ⚠️ Conflicted

Several randomized trials of standardized extracts (often combined with other ingredients) report reductions in body weight, waist circumference, and body fat, alongside improvements in cholesterol and fasting blood sugar. The proposed mechanism is reduced fat-cell formation and appetite signaling. The evidence is directly conflicted: a plant-specific meta-analysis found significant benefit for combination products, yet a broader, independent meta-analysis of weight-loss herbs judged the same signal to rest on very few, small, poorly reported studies and concluded the evidence was insufficient to recommend it. Many positive trials also came from the extract’s commercial developer, and several used formulas containing additional active ingredients, making the plant’s independent contribution hard to isolate.

Magnitude: In pooled trials of combination products, roughly 5 kg greater weight loss versus placebo over 8–12 weeks, with fasting blood sugar about 10 mg/dL and LDL (low-density lipoprotein, the “bad” cholesterol linked to heart disease) about 14 mg/dL lower.

Fracture Healing and Bone Pain Relief

The plant’s oldest and best-supported use is accelerating the healing of broken bones and easing associated pain, consistent with cell and animal work showing it stimulates bone-forming cells and mineral deposition. Human evidence includes several small trials and case series in fractures and jaw/dental bone procedures, and a meta-analysis of randomized trials found a significant reduction in bone pain and a benefit for fracture healing. Certainty remains low: trials are small, methods vary, and standardized extracts differ, so the size of the effect is uncertain even though the direction is consistent.

Magnitude: A meta-analysis of nine randomized trials found a statistically significant reduction in bone pain, and individual fracture trials report faster radiographic bone union versus untreated controls; a precise average effect is not quantified.

Low 🟩

Anti-Osteoporotic and Bone-Turnover Support

Beyond acute fractures, the plant is proposed to slow age- and menopause-related bone loss, supported by strong animal models where it improves bone density and microarchitecture in estrogen-deficient states. In humans the data are thin: a controlled trial in postmenopausal women reported stabilization of bone-turnover markers over several months, and meta-analysis found it raises parathyroid hormone (PTH, a hormone that regulates blood calcium and bone remodeling) without clear short-term gains in bone mineral density. It is best viewed as a possible add-on for early bone loss rather than a replacement for established therapy.

Magnitude: A 24-week trial stabilized bone-turnover markers with no significant short-term change in bone mineral density (BMD, a measure of bone strength).

The plant is popular among strength and endurance athletes for reducing exercise-associated joint pain and supporting tendon and ligament recovery, plausibly through its anti-inflammatory and collagen-supportive actions. Human support is limited to small trials and abundant anecdote; the effect, if real, appears modest and short-term data dominate.

Magnitude: Not quantified in available studies.

Antioxidant and Anti-Inflammatory Activity

Rich in polyphenols and vitamin C, the extract scavenges free radicals and lowers inflammatory signaling in laboratory and animal systems, the general theme most relevant to longevity. Direct human confirmation with clinical endpoints is sparse, and effects on markers such as CRP (C-reactive protein, a general marker of inflammation) have not been consistently quantified in people.

Magnitude: Not quantified in available studies.

Speculative 🟨

Insulin Sensitization and Diabetic-Complication Protection

Animal studies suggest the extract improves insulin sensitivity (in part via AdipoR1) and protects against diabetes-related kidney, heart, and nerve damage through antioxidant and anti-inflammatory pathways. This is mechanistically interesting for metabolic longevity but rests entirely on preclinical models, with no controlled human outcome data.

Neuroprotective, Analgesic, and Anticonvulsant Effects

Traditional use for pain and seizures is echoed by animal studies reporting analgesic, anti-inflammatory, and anticonvulsant activity, and by cell work suggesting protection of nerve tissue. The basis is mechanistic and anecdotal only; no human trials support these uses.

General Longevity and Healthspan

The combination of antioxidant, anti-inflammatory, metabolic, and bone-supportive actions has led to interest in the plant as a broad healthspan agent. There are no human studies of aging, lifespan, or long-term healthspan endpoints, so this remains hypothesis based on mechanism only.

Benefit-Modifying Factors

  • Genetic factors: No pharmacogenetic variants are established for Cissus quadrangularis. Because part of the bone effect is attributed to weak estrogen-like activity, variation in estrogen-receptor genes could in theory modify the bone response, but this has not been studied in humans.

  • Baseline biomarker levels: Benefit is likely greatest where there is room to improve — for example, people with elevated body weight, high fasting blood sugar, raised LDL cholesterol, or low bone density. Those already at optimal metabolic and bone markers should expect smaller changes.

  • Sex-based differences: Much of the anti-osteoporotic evidence comes from estrogen-deficient (postmenopausal) female models, suggesting women in or after menopause may be the group most likely to benefit for bone endpoints; metabolic and fracture-healing benefits appear in both sexes.

  • Pre-existing health conditions: Overweight, metabolic syndrome, osteopenia, recent fracture, or recovery from bone/dental surgery represent the states where the current evidence suggests the most plausible benefit.

  • Age-related considerations: Older adults, including those at the upper end of the target range, face the highest fracture and bone-loss risk and are the most-studied bone population; however, they also more often take medications for blood sugar or blood pressure, so additive effects should be tracked.

Potential Risks & Side Effects

Content below is framed for the risk-aware, health-optimizing adult. Cissus quadrangularis has an unusually clean safety record: animal toxicity studies place the lethal dose above 3,000 mg/kg, and human trials report no serious adverse events. A dedicated search of trial reports, review articles, and drug-reference and case-report sources was performed to compile the profile below.

Medium 🟥 🟥

Mild Digestive and Nervous-System Effects

The most commonly reported side effects are mild and short-lived: intestinal gas, loose stools or diarrhea, dry mouth, headache, and occasional trouble sleeping. The proposed basis is direct gut irritation and, for headache and insomnia, stimulation — though notably several of these reports come from combination products that also contained caffeine or green-tea extract, so the plant alone may be even better tolerated. In controlled trials these events were infrequent and generally comparable to placebo, and they typically resolve with continued use or dose reduction.

Magnitude: Mild and transient; in controlled trials adverse-event rates were low and broadly similar to placebo, largely limited to gas, loose stools, headache, or dry mouth.

Low 🟥

Additive Blood-Sugar Lowering

Because the extract can modestly lower fasting blood sugar, combining it with diabetes medication or other glucose-lowering supplements could in principle push blood sugar too low (hypoglycemia — abnormally low blood sugar causing shakiness, sweating, or confusion). This is a plausible pharmacological effect rather than a documented pattern of harm, and it is most relevant to people already treated for diabetes.

Magnitude: Not quantified in available studies.

Speculative 🟨

Thrombocytopenia (Isolated Case Report)

A single published case described a fall in platelet count (thrombocytopenia — too few clotting cells, which can raise bleeding risk) in a kidney-transplant recipient taking the supplement, which recovered on stopping it. This is one isolated report in an immunosuppressed patient and cannot establish a general risk, but it warrants caution in transplant or immune-compromised individuals.

Theoretical Bleeding and Antiplatelet Interaction

Some plant constituents have mild blood-thinning or antiplatelet activity in laboratory settings, raising a theoretical concern about increased bleeding when combined with anticoagulants or before surgery. No human bleeding events have been attributed to the plant; the concern is mechanistic and precautionary.

Unknown Safety in Pregnancy and Lactation

There are no adequate human safety data during pregnancy or breastfeeding, and the plant’s weak estrogen-like activity provides a theoretical reason for caution. In the absence of evidence, use in these groups cannot be considered established as safe.

Risk-Modifying Factors

  • Genetic factors: No genetic variants are known to modify the plant’s risk profile. Its metabolism through specific liver enzymes is uncharacterized, so enzyme-based genetic risk cannot currently be assessed.

  • Baseline biomarker levels: Individuals with already-low fasting blood sugar, low platelet counts, or those on tight glycemic control have the least margin and the greatest chance of experiencing additive effects.

  • Sex-based differences: No sex-specific safety differences have been established. The theoretical estrogen-like activity is the main sex-relevant consideration, chiefly for hormone-sensitive conditions in women.

  • Pre-existing health conditions: Diabetes (glucose-lowering additive effect), bleeding disorders or upcoming surgery (theoretical antiplatelet effect), organ transplant or immunosuppression (case-report thrombocytopenia), and hormone-sensitive conditions warrant the most caution.

  • Age-related considerations: Older adults, including those at the upper end of the target range, are more likely to be on multiple medications (for blood sugar, blood pressure, or blood thinning), which raises the practical chance of additive interactions even though the plant itself is well tolerated.

Key Interactions & Contraindications

  • Prescription drug interactions: Antidiabetic medications (metformin, sulfonylureas such as glipizide, insulin) may combine additively with the extract’s glucose-lowering effect — caution; monitor for hypoglycemia and consider spacing or dose review. Anticoagulant and antiplatelet drugs (warfarin, clopidogrel) carry a theoretical caution for increased bleeding based on mechanism only. Antihypertensive drugs could in theory be potentiated given animal blood-pressure effects — caution; monitor blood pressure.

  • Over-the-counter medication interactions: Non-prescription pain relievers with blood-thinning activity (aspirin, ibuprofen and other NSAIDs — non-steroidal anti-inflammatory drugs) share the same theoretical bleeding caution. Over-the-counter antacids and calcium products have no established interaction.

  • Supplement interactions: Other glucose-lowering supplements (berberine, chromium, alpha-lipoic acid) and blood-thinning supplements (fish oil, high-dose vitamin E, ginkgo, garlic) may add to the extract’s respective effects — caution; monitor.

  • Additive-effect supplements: For bone goals, the plant is commonly and sensibly paired with calcium, vitamin D, vitamin K2, and magnesium, which act on the same bone-building pathways; this is generally complementary rather than a hazard, but total calcium intake should be tracked.

  • Other interactions: As a botanical with uncharacterized liver-enzyme handling, interactions with narrow-therapeutic-index drugs cannot be fully excluded and remain an open question.

  • Populations who should avoid or use only with medical oversight: Pregnant or breastfeeding individuals (avoid — no safety data); people scheduled for surgery (discontinue at least 2 weeks beforehand due to glucose and theoretical bleeding effects); organ-transplant recipients and others on immunosuppression (avoid or use only under supervision, given a case report of low platelets); and people with diabetes on medication (use only with glucose monitoring).

Risk Mitigation Strategies

  • Low starting dose with gradual increase: Protocols typically begin at the low end of the range (about 500 mg once or twice daily) for 1–2 weeks before increasing, which limits the mild digestive and headache effects that are the most common complaints.

  • Dosing with food: Taking the extract with meals reduces gas, loose stools, and stomach upset, the plant’s most frequent side effects.

  • Blood-sugar monitoring in diabetes: Where glucose-lowering medication is used, blood sugar is monitored regularly at the start and after dose changes to catch additive lowering before it reaches hypoglycemia, with any medication adjustment left to the prescribing clinician.

  • Pre-surgical pause: The supplement is commonly stopped at least 2 weeks before planned surgery or dental extraction to avoid the theoretical bleeding and blood-sugar effects during the procedure.

  • Caution in undocumented-safety groups: Use is avoided during pregnancy or breastfeeding and in organ-transplant or immunosuppressed states unless supervised, mitigating the unknown reproductive risk and the isolated low-platelet report.

  • Third-party-tested products: Third-party-tested, standardized extracts reduce the risk of heavy-metal contamination or mislabeling, mitigating quality-related harm rather than a pharmacological one.

Therapeutic Protocol

  • Standard oral protocol: Leading practitioners and product labels typically use 500–1,000 mg of a standardized aerial-part (stem) extract, taken once or twice daily with food. For fracture and bone-healing use, courses commonly run 6–12 weeks; for metabolic and weight goals, trials generally dosed for 8–12 weeks.

  • Competing approaches: A conventional integrative approach uses whole-plant or generically standardized powder for bone and joint support, while the metabolic approach favors the specific aqueous stem-and-leaf extract (CQR-300) studied for weight and metabolic syndrome. Neither is clearly superior; the choice tracks the goal (bone/joint versus metabolic) rather than one being the default.

  • Popularizing sources: The bone-healing tradition traces to Ayurvedic and Siddha practice and to mid-twentieth-century Indian researchers; the standardized metabolic extract (CQR-300) was developed and popularized by the commercial research group associated with Julius Oben.

  • Best time of day: Timing is not well studied; taking it with meals is standard, and splitting the dose to breakfast and dinner is common. If mild sleep disturbance occurs, an earlier-in-the-day schedule is preferred.

  • Half-life: The pharmacokinetics and half-life of the plant’s active constituents in humans are not well characterized, which is why twice-daily dosing is generally used rather than a single dose.

  • Single versus split dosing: Split dosing (twice daily) is the common practice, both to maintain exposure given the unknown half-life and to reduce digestive side effects from a large single dose.

  • Genetic considerations: No pharmacogenetic markers — such as APOE4 (a gene variant affecting fat and cholesterol handling), MTHFR (a gene for an enzyme that processes folate), or COMT (a gene for an enzyme that breaks down certain neurotransmitters) — are established for dose selection; genotype-guided dosing is not currently possible.

  • Sex-based differences: Women in or after menopause are the group in whom bone benefits are best supported, which may inform who pursues a bone-focused course; dosing itself is not sex-specific in the literature.

  • Age-related considerations: Older adults, including those at the upper end of the target range, are the primary bone population and may combine it with calcium and vitamin D, but should have concurrent medications reviewed before starting.

  • Baseline biomarkers: Baseline body weight, fasting blood sugar, lipid panel, and (for bone goals) bone density and turnover markers help define who is likely to benefit and provide a reference for tracking response.

  • Pre-existing conditions: Presence of metabolic syndrome, osteopenia, or recent fracture supports a targeted course, whereas diabetes on medication, bleeding risk, or immunosuppression calls for the cautions noted above.

Discontinuation & Cycling

  • Lifelong versus short-term: Use is typically goal-directed and time-limited rather than lifelong — for example, a defined course during fracture healing or a 8–12 week metabolic trial — after which its continued value is reassessed against objective markers.

  • Withdrawal effects: No withdrawal syndrome or rebound effect has been reported; the supplement can be stopped without tapering from a safety standpoint.

  • Tapering: No tapering protocol is required or described. The main practical reason to stop in advance is the pre-surgical pause noted above.

  • Cycling: There is no evidence that cycling is needed to maintain effectiveness or to avoid tolerance; decisions to continue, pause, or repeat a course are best driven by whether tracked markers (weight, blood sugar, bone healing) are improving.

  • Practical framing: Because the plant is inexpensive and well tolerated, many users simply continue for the duration of a bone- or metabolic-focused goal and then discontinue, restarting only if the same goal recurs.

Sourcing and Quality

  • Source and form: Products derive mainly from the plant’s aerial parts (the characteristic square stems). Common forms are dried powder in capsules and standardized extracts; the metabolic research used a specific aqueous stem-and-leaf extract (CQR-300).

  • What to look for: Prefer extracts standardized to a stated marker content (often expressed as a percentage of ketosterones or total polyphenols), with clear labeling of the plant part and extract ratio, and independent third-party testing for identity, potency, and contaminants.

  • Third-party testing: Because botanicals are prone to adulteration, heavy-metal contamination, and species substitution, certification from an independent laboratory or program (for example, seals indicating third-party verification) is the key quality signal to seek.

  • Reputable options: Standardized branded extracts (such as CQR-300) and products from established supplement brands that publish certificates of analysis are preferable to unbranded bulk powders of uncertain origin.

Practical Considerations

  • Time to effect: For fracture and bone-pain use, benefits in trials emerge over several weeks (commonly a 6–12 week course); for weight and metabolic markers, changes were measured over roughly 8–12 weeks. It is not an acute, same-day intervention.

  • Common pitfalls: Expecting rapid or dramatic results; using unstandardized, unverified powder; assuming combination-product results apply to the plant alone; and overlooking additive blood-sugar effects when already on diabetes medication.

  • Regulatory status: In the United States and most markets it is sold as a dietary supplement, not an approved drug, so it is not evaluated for efficacy by regulators and product quality varies by manufacturer.

  • Cost and accessibility: It is inexpensive and widely available online and in supplement stores, so cost and access are not meaningful barriers.

Interaction with Foundational Habits

  • Sleep: Indirect and usually neutral. A minority of users — often with caffeine-containing combination products — report mild trouble sleeping, so if the extract is taken alone and any sleep disturbance appears, shifting the dose earlier in the day is a reasonable adjustment.

  • Nutrition: Direct and complementary for bone goals. Taken with food to limit digestive upset, it pairs logically with adequate protein, calcium, vitamin D, vitamin K2, and magnesium, which supply the raw materials for the bone-building pathways it is thought to stimulate; total calcium intake should still be kept within sensible limits.

  • Exercise: Indirect and potentially supportive. Its popularity among athletes centers on reduced exercise-related joint pain and connective-tissue recovery; there is no evidence it blunts training adaptations such as muscle growth, and it is typically taken with meals rather than timed tightly around workouts.

  • Stress management: Indirect and minor. Through antioxidant and anti-inflammatory activity it may modestly counter the oxidative load of chronic stress, but there is no direct human evidence of effects on cortisol or the stress response, so it should not be relied on for this purpose.

Monitoring Protocol & Defining Success

A baseline that matches the goal — metabolic markers for weight/metabolic use and bone markers for bone use — allows response to be judged objectively rather than by feel. A practical cadence is a baseline test, a re-check of relevant markers at about 8–12 weeks (the typical trial duration), and then every 6–12 months if use continues.

  • Baseline testing is obtained before the first dose and interpreted against the person’s goal, health conditions, and current medications.

  • Ongoing monitoring follows the cadence above: an early re-check near the end of a first course (about 8–12 weeks), then every 6–12 months for continued use, with more frequent blood-sugar checks for anyone on diabetes medication.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting blood glucose 75–86 mg/dL Tracks the metabolic benefit and guards against additive lowering Fasting sample; check more often if on diabetes medication (risk of hypoglycemia — low blood sugar)
HbA1c < 5.4% Average blood sugar over ~3 months; confirms durable metabolic change HbA1c = glycated hemoglobin; no fasting needed; conventional “normal” is < 5.7%
Lipid panel (LDL, HDL, triglycerides) LDL < 100 mg/dL; HDL > 50 mg/dL; triglycerides < 90 mg/dL Captures the cholesterol/triglyceride changes seen in trials Fasting 9–12 h preferred; HDL = high-density (“good”) cholesterol
Body weight / waist circumference Waist < 94 cm (men), < 80 cm (women) Primary endpoint for weight/metabolic goals Measure same time of day; waist tracks central fat better than weight alone
Serum calcium 9.2–10.0 mg/dL Safety and bone context, especially if co-supplementing calcium Pair with albumin for correction; avoid over-supplementation
Alkaline phosphatase (ALP) 40–90 U/L Bone-formation marker for bone-healing goals ALP = an enzyme raised during active bone building; also liver-derived
Parathyroid hormone (PTH) 15–45 pg/mL The one bone marker meta-analysis found the plant raises PTH regulates blood calcium; interpret with calcium and vitamin D
25-hydroxy vitamin D 40–60 ng/mL Vitamin D underpins any bone benefit 25-hydroxy vitamin D is the storage form; morning sample typical
Platelet count 150–400 ×10⁹/L Screens for the rare low-platelet signal from a case report Part of a complete blood count; chiefly relevant if immunosuppressed
ALT / AST ALT < 25 U/L (men), < 20 U/L (women) General safety check for any long-term botanical Liver enzymes; conventional upper limits are higher (~40 U/L)

Qualitative markers matter alongside labs:

  • Bone or joint pain and, where relevant, healing progress or return of function.

  • Energy levels and general sense of wellbeing.

  • Digestive comfort (gas, stool changes) as an early tolerance signal.

  • Sleep quality, particularly if using a caffeine-containing combination product.

Emerging Research

Content below is framed for the health-optimizing adult tracking where the evidence may move next, on both supportive and skeptical sides.

  • Appetite-hormone metabolic trial: An active controlled trial is testing aqueous extracts of Cissus quadrangularis and Dichrostachys glomerata on the appetite-and-glucose hormone GLP-1 (a gut hormone that curbs appetite and improves blood sugar) and on DPP-4 (the enzyme that breaks GLP-1 down) in overweight and obese adults (NCT06827002; early-phase, 248 participants) — a direct test of a proposed metabolic mechanism.

  • Metabolic-health formula trial: A not-yet-recruiting randomized trial (MB-1) will evaluate a multi-ingredient metabolic-health product containing Cissus quadrangularis against placebo for change in body weight in overweight and obese adults (NCT07363148; 120 participants) — relevant to whether the metabolic signal holds in a modern controlled design.

  • Bone-regeneration and dental applications: A completed randomized trial examined the plant’s bone-forming potential in jaw-ridge distraction and dental-implant sites (NCT04669795; 20 participants), reflecting active interest in localized bone-healing and biomaterial delivery uses.

  • Fat-cell “browning” mechanism (supportive direction): A human-tissue randomized study found the extract raised UCP1 and reduced central fat, suggesting a heat-generating fat-cell mechanism worth confirming in larger metabolic trials (Chatree et al., 2021).

  • Bone immunology (supportive direction): Preclinical work reports the plant blocks bone-dissolving-cell formation and improves bone health in an estrogen-deficient osteoporosis model by modulating the immune–bone axis, pointing to osteoporosis prevention as a future human research target (Azam et al., 2023).

  • Skeptical direction — evidence quality: The most rigorous recent meta-analysis of bone biomarkers rated the certainty of evidence as very low and found no clear bone-density benefit, so well-designed, adequately powered human trials could just as easily narrow the plant’s apparent effects as confirm them (Na Takuathung et al., 2025).

Conclusion

Cissus quadrangularis is an inexpensive, traditionally used plant with a remarkably clean safety record and a long reputation for helping bones heal. The most consistent human signals are for faster fracture healing and reduced bone pain, and for modest improvements in body weight, blood sugar, and cholesterol — though the weight findings lean heavily on small studies, combination products, and research tied to the extract’s commercial developer, which is an important reason to read them cautiously. Its broader promise for bone-density protection, joint comfort, and general metabolic and longevity support rests mainly on animal and laboratory work that has not yet been confirmed in people.

The overall quality of the evidence is low: trials are small, methods and extracts vary, and the most careful recent analyses rate their confidence as very low. What stands out instead is how well tolerated the plant is, with only mild and short-lived side effects reported. For someone weighing a low-cost, low-risk option and willing to track objective markers over a defined period, the plant is a reasonable thing to understand — while recognizing that the science supporting it remains early and unsettled rather than proven, and that the same future trials could strengthen or shrink its apparent benefits.

Top - Benefits - Risks - Protocol